# 财报详情 Q4财报亮点 总体收入为 6.01亿美元 ，按报告和固定汇率计算增长9%； 医疗保健收入为 3.68亿美元 ，按报告计算增长8%，按固定汇率计算增长9%； 非医疗保健收入为 2.32亿美元 ，按报告和固定汇率计算增长11%； 合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年2月26日，迈心诺Masimo（纳斯达克股票代码：MASI） 公布了超出市场预期 的 第 四季度财务业绩 ，并 上调 了2025年全年盈利指引 。 早盘交 易中，MASI股价上涨 超过8% ，达到每股 184美 元 。 Masimo 公司在2024年经历了一段动荡时期。创始人兼时任首席执行官Joe Kiani在9月辞职，此前股东投票将他从董事会主席职位上罢免，结束了Masimo 与Politan Capital Management之间漫长的代理权争夺战。几个月内，公司总部还进行了裁员。 基本每股GAAP净亏损为（6.52美元），其中包括对Sound United的商誉和无形资产减值； 非 GAAP稀释每股净 ...

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $18,500,000, reflecting a 41% growth compared to $13,100,000 in Q4 2023 [21] - Full year revenue totaled $65,400,000, representing a 45% growth over 2023 [21] - Gross margin for Q4 2024 was 88%, up from 85% in the prior year [22] - Full year gross margin was 87%, compared to 84% in 2023 [22] - Net loss for Q4 2024 was $12,600,000, or a loss of $0.40 per share, compared to a loss of $8,300,000, or a loss of $1.53 per share in Q4 2023 [25] - Full year net loss was $40,500,000, or a loss of $3.39 per share, compared to a loss of $29,500,000, or a loss of $5.56 per share in 2023 [25] Business Line Data and Key Metrics Changes - Product revenue for Q4 2024 was $14,100,000, a 41% increase from $10,000,000 in Q4 2023 [21] - Subscription revenue for Q4 2024 was $4,400,000, representing a 40% increase from $3,100,000 in Q4 2023 [21] - Active accounts increased to 529 as of December 31, 2024, with an addition of 25 accounts during Q4 [11] Market Data and Key Metrics Changes - The company targets approximately 5,500 remaining prospective accounts in the U.S. acute care facilities market [11] - The current market opportunity for seizure detection and management in acute care settings is estimated at $2,000,000,000 [19] Company Strategy and Development Direction - The company aims to expand its account acquisition team to 55 territory managers by mid-2025 [14] - Plans to invest in optimizing algorithm performance and user experience while expanding indications beyond seizure management [15] - The company envisions EEG becoming a new vital sign, with a focus on developing algorithms for various neurological conditions [16] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a catalyst-heavy year with significant growth opportunities [19] - The company expects full year 2025 total revenue to be in the range of $81,000,000 to $85,000,000, representing annual growth of 24% to 30% over 2024 [26] - Management remains focused on achieving cash flow breakeven and is optimistic about the strength of the balance sheet [28] Other Important Information - The company has made significant strides in commercial growth and R&D pipeline development, impacting tens of thousands of patients [6] - The transition to operating as a public company has increased stock-based compensation costs, expected to contribute approximately $15,000,000 to operating expenses for 2025 [29] Q&A Session Summary Question: Can you elaborate on the guidance for this year and the underlying assumptions? - Management indicated that investments in sales infrastructure started in Q3 and will continue through mid-2025, leading to accelerated growth in 2026 and beyond [34] Question: What are the thoughts on new account adds and traction in Q4? - The strength of Q4 was attributed to good planning, allowing some launches that would have occurred in Q1 to be pulled forward [38] Question: What are the expectations for gross margin and OpEx spend in 2025? - Gross margins are expected to normalize to the mid to high 80% range, while R&D expenses are anticipated to increase by 40% to 60% year over year [41] Question: Can you provide updates on the stroke detection algorithm development? - The company is pleased with the progress in the stroke trial and plans to expand enrollment speed to collect more patient data for algorithm training [52] Question: What are the expectations for account penetration and utilization? - The company expects an upward trajectory in usage, although purchasing patterns may vary based on customer preferences [70]

Novanta (NOVT) Q4 2024 Earnings Call February 25, 2025 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader & IRMatthijs Glastra - Chair and Chief Executive OfficerRobert Buckley - CFOLee Jagoda - Senior Managing DirectorBrian Drab - Co-Group Head–Industrials Conference Call Participants Robert Mason - Senior Research Analyst Operator Good morning. My name is Gary, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated's Fourt ...

Financial Data and Key Metrics Changes - For the third quarter ended December 31, 2024, revenue increased by 21.7% year over year to $3.6 million, reflecting the effectiveness of the company's technology and strategic initiatives [7] - Gross profit for the quarter totaled $2.8 million, up 27.5% from $2.1 million in the prior year period, with gross profit percentage improving to 76.4% from 72.9% [10] - Net loss attributable to common stockholders decreased 56.7% year over year to $1.32 million, or $0.054 per share, from a net loss of $3.05 million, or $0.339 per share, in the same quarter of the previous fiscal year [13] - Adjusted EBITDA improved to negative $110,000 for the quarter, a reduction of about $1 million in negative adjusted EBITDA from the comparative period of the prior fiscal year, marking a 90% improvement [14] Business Line Data and Key Metrics Changes - Recurring revenue from the Technology as a Service subscription model and usage-based subscriptions remains robust, driven by the popularity of FDA-cleared cardiac monitor devices, particularly the BioCore suite [6] - Flat fee revenue grew by about 22% year over year, with technology fees rising by 21.8% year over year to approximately $3.4 million, of which 67% was flat fee revenue [9] Market Data and Key Metrics Changes - The company is expanding its market reach beyond cardiology through strategic alliances with top group purchasing organizations and specialist organizations in neurology and pulmonology [3][4] - The focus on chronic care disease prevention and management is expected to reinforce the company's market position as demand for its suite of products grows [19] Company Strategy and Development Direction - The company is committed to advancing the commercialization of its BioCore and BioCare products, with a focus on innovation and operational efficiency to drive sustained growth and profitability [17][20] - Plans for 2025 include expanding into new vertical segments and leveraging partnerships to enhance market penetration [18][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to maintain cash flow improvements while investing in commercial growth, particularly in larger deals [22][23] - The management team is optimistic about achieving profitability, citing record margins and a strong competitive position in the cardiac monitoring landscape [35][36] Other Important Information - The company has successfully transitioned approximately three-quarters of its business to a flat fee subscription model, establishing a higher quality and more predictable revenue stream [9] - The company is strategically transforming its sales force to focus on longer sales cycles and larger accounts, including independent hospitals and GPO networks [12] Q&A Session Summary Question: Sustainability of cash flow improvement - Management believes the cash flow improvement is sustainable and plans to reinvest in commercial growth while maintaining a prudent approach to investments [22][23] Question: Details on expansion into new verticals in 2025 - The company is expanding into complementary areas such as remote monitoring and implantable management, responding to customer requests for broader applications of its technology [24][25][27] Question: Goals for international expansion in 2026 - The company is focused on opportunistic international expansion, primarily in Canada, Germany, and Denmark, leveraging existing partnerships rather than establishing new offices [29][30][31]

2024年2月14日，Kestra Medical 提交了一份S-1表格，确认其计划通过首次公开募股（IPO）上市，并且设定了筹集约1亿美元的目标。 Kestra Medical 是一家专注于开发创新医疗设备的公司，致力于通过先进的技术改善心脏健康管理，其核心产品是可穿戴式心脏复律除颤器（Wearable Cardioverter Defibrillator, WCD），旨在为高风险患者提供持续的心脏监测和保护。 自动检测与治疗： 当检测到危及生命的心律失常（如心室颤动或心动过速）时， 设备能够自动提供电击治疗，以恢复正常心律。 这种自动化的功能是其核 心优势之一，能够在患者无意识或无法自救的情况下，迅速采取行动。 记录其他心律失常： 除了能够处理危及生命的心律失常外，ASSURE WCD还能 检测和记录其他可能需要临床干预的心律失常 。这为医生提供了更全面的 患者心脏活动数据，有助于后续的诊断和治疗。 此外，该系统还 兼容 Kestra Medical 的数字健康平台，方便患者和医生及时进行通信。 平台通过大量的个人数据整理，通过终端呈现给患者，促进患者参 与自己的康复过程。 # A S S U R E W ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology index rose by 6.02% during the period from February 5 to February 14, outperforming the Wind All A index (5.3%) and the CSI 300 index (3.19%) [2][7] - The AI + healthcare sector continues to strengthen, with sequencing and large models being the strongest directions [2][7] - The introduction of the medical insurance imaging cloud index by the National Medical Insurance Bureau aims to facilitate medical data sharing, reduce redundant examinations for patients, and enhance the efficiency of medical services [2][11] - Chinese innovative pharmaceutical companies are reshaping the global pharmaceutical innovation landscape by leveraging high-quality, low-cost talent and a progressive innovation approach [2][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology index increased by 6.02%, with hospitals (14.31%), medical devices (12.54%), and medical research outsourcing (10.57%) showing strong performance [7][8] - The top three performing stocks were BGI Genomics (75.25%), Dian Diagnostics (73.59%), and Meinian Health (49.08%) [9] Industry News and Key Company Announcements - The National Medical Insurance Bureau launched the medical imaging cloud index to improve data sharing among medical institutions [11] - Anke Bio plans to invest over 200 million yuan in Weisheng Pharmaceutical, focusing on long-acting growth hormone therapies [12] - The report highlights various collaborations and approvals in the industry, including partnerships for drug development and clinical trial advancements [14][16]

2025年2月13日，GE Healthcare（纳斯达克股票代码：GEHC）股价上涨，其2024年第四季度业绩超出调整后的每股收益（EPS）预期。截至13日下午交 易时段，GEHC的股价上涨 超过9% ，达到每股 93.79美元 。 GE医疗报告了 7.37亿美元 的利润，第四季度销售额达到 53.2亿美元 （约合388亿人民币） ，每股收益为1.57美元。 经过调整，剔除一次性项目后，每股 收益为1.45美元，比华尔街预期高出19美分。销售额几乎与预期持平，专家此前预测的收入为53.3亿美元。 | Revenues | Organic orders growth **(1) | Adjusted EBIT* and Adjusted EBIT margin* | Adjusted EPS* | Free cash flow* | | --- | --- | --- | --- | --- | | S5.3B | 6% YoY | S994M | SI 45 | S811M | | 2% Organic growth*14 | Book-to-Bill** | 18.7% Margin | +23% YoY ...

2025年2月10日，Inspire Medical Systems（纽约证券交易所代码：INSP）公布了截至2024年12月31日的季度和年度财务业绩。公司2024年第四季度收入为2.397亿美 元，同比增长25%。 2024年全年收入为 8.028亿美元 （约合人民币59亿元），同比增长 28% 。 Inspire Medical Systems 是一家专注于开发和商业化创新性、微创性治疗方案的医疗技术公司，旨在为阻塞性睡眠呼吸暂停患者提供解决方案。 # 近期业务亮点及2025年全年指引 公司董事长兼首席执行官蒂姆·赫伯特（Tim Herbert）表示："我们对第四季度的强劲表现感到非常兴奋，收入同比增长25%，运营收入接近3,200万美元， 每股摊薄净收入同比增长135%。在本季度，我们稳步推进Inspire V的全面上市，优化领导团队以推动未来增长，持续提升盈利能力，启动了7,500万美元的 加速股票回购计划，并达到了一个重要的里程碑，超过9万名患者接受了Inspire疗法。我们期待在2025年借助Inspire V的上市继续保持强劲表现。" ▲图片源自公司官网（下同） # 2024年第四季度财务业绩 ...

以下文章来源于动脉网 ，作者赵泓维 作者 | 赵泓维 来源 | 动脉网 （ID：vcbeat） 医疗设备厂商的日子近来不太好过。 国信证券的一份调研报告显示：2024年上半年全国医疗设备中标总金额仅为520亿元， 同比降幅高达35%。 动脉网 . 动脉网（www.vbdata.cn）聚焦于技术驱动下生命健康领域产业创新和变革的报道与研究。 设备销量放缓。 其中，磁共振、CT、超声、内窥镜、监护设备的形势尤为严峻，以上品类中标金额分别 为65亿、65亿、60亿、45亿和10亿；对应降幅-40%、-40%、-40%、-50% 和-50%，每一类设备的销量都几近腰斩。 2023Q1-2024Q2医疗设备重要品类中标金额情况（单位：亿元；数据来源：国信证 券） 宏观下的萧条给予了每一家企业同等体验。无论国产龙头迈瑞联影，还是跨国巨擘 GPS，这半年间交出的答卷都不尽如人意。 如今凛冬已至，医学设备的转机还有多远？ 设备销量放缓，企业到底承了多少压？ 医疗设备市场急速缩紧背后，一个最为明显的原因是2023年年中开启的医药反腐风暴。 作为此次行动的重灾区，医疗器械相关的违法操作层出不穷。很多医院管理者通过虚报 费用、收受 ...

特别提示 四川港通医疗设备集团股份有限公司（以下简称"港通医疗"或"发行人"） 首次公开发行2,500.00万股人民币普通股（A股）并在创业板上市（以下简称"本 次发行"）的申请已经深圳证券交易所（以下简称"深交所"）创业板上市委员会 审议通过，并已获中国证券监督管理委员会同意注册（证监许可〔2023〕1108 号）。发行人股票简称为"港通医疗"，股票代码为"301515"。 发行人与本次发行的保荐人（主承销商）中信建投证券股份有限公司（以下 简称"保荐人（主承销商）"）协商确定本次发行价格为人民币31.16元/股，本 次发行股份数量为2,500.00万股。 本次发行价格未超过剔除最高报价后网下投资者报价的中位数和加权平均 数以及剔除最高报价后通过公开募集方式设立的证券投资基金、全国社会保障基 金、基本养老保险基金、企业年金基金和职业年金基金、符合《保险资金运用管 理办法》等规定的保险资金和合格境外投资者资金报价中位数和加权平均数的孰 低值，故保荐人相关子公司无需参与本次发行的战略配售。 本次发行不安排向发行人的高级管理人员和核心员工资产管理计划及其他 外部投资者的战略配售。依据本次发行价格，保荐人相关子公司 ...